N116Y, H-RAS mutant, has dominant negative activity in the RAS function and a suppressive effect on the growth of various types of cancer cells.
Introduction
Deaths from cancer are increasing every year. Using combined therapeutic strategies such as surgical treatment, chemotherapy, radiotherapy, the curability of advanced cancer remains insufficient. Therefore, the development of new concepts for cancer treatment is important. Gene therapy is a promising therapeutic option for cancer therapy 1) . The purpose of cancer gene therapy is to kill the cancer cells with various strategies [2] [3] [4] [5] [6] [7] .
RAS, a proto-oncogene product, regulates survival, proliferation, differentiation, and cell motility. With RAS mutation, oncogenic RAS is observed in various types of cancer, so RAS suppression is one of the promising options for cancer gene therapy. We originally constructed a dominant negative RAS mutant N116Y 8) . The N116Y gene is a mutant derived from v-H-RAS oncogene by substituting the codon for asparagine-116 with tyrosine. We already reported that N116Y is a potential candidate for cancer gene therapy which has a suppressive effect on pancreatic cancer, esophageal cancer and bladder cancer in vitro and in vivo [8] [9] [10] [11] [12] [13] [14] ; however, replication errors or reversion of N116Y are potential concern for carcinogenesis in clinical application because N116Y is derived from the v-H-RAS oncogene. We constructed a C-terminal deletion dominant negative RAS mutant and investigated its suppressive effect on cancer in vitro and in 4 vivo.
Materials and Methods

Construction of modified dominant negative RAS mutant
To construct serial C-terminal deletion mutants, the N116Y gene 15) in a retrovirus vector pZIP was digested by EcoRI and a fragment was removed respectively. The amplified N116Y or modified N116Y gene was inserted into pCMV-3xFLAG vector. pCMV-3xFLAG contains the neomycin resistance gene and the fusion protein of N116Y or modified N116Y and 3 x FLAG tag is expressed under the transcriptional regulation of CMV promoter. Moreover, 5 Green Fluorescent Protein (GFP), β-galactosidase or modified N116Y genes were inserted into pAd-Track-CMV vector (kindly provided by Dr. Bert Vogelstein of The Johns Hopkins University) 16) .
Cell lines
The human colon cancer cell lines SW480 and LoVo, and the human tongue Colony inhibition assay 2 x 10 4 LoVo cells in 12-well plates were transfected with 0.6 μg of pCMV-3xFLAG, 0.6 μg of pCMV-3xFLAG inserted in N116Y gene and 0.6 μg pCMV-3xFLAG inserted in N116Y-Cdel2 gene by Lipofectamine, respectively. Transfected cells were harvested, then 1/10 of these cells were cultured in 6 cm dishes with 0.7 mg/ml neomycin-containing medium. Ten days later, the number of neomycin colonies (colonies with a diameter > 1 mm) was counted. 8 The average of triplicate experiments is presented.
Gene transfection and analysis of tumor cells in vivo
We used the method of gene transfection with the hemagglutinating virus of Japan (HVJ) envelope vector (GenomONE-Neo, Ishihara Sangyo Kaisha, Osaka, Japan). First, 1 x 10 7 LoVo cells were subcutaneously injected into the back of nine nude 5-week-old female KSN/Slc mice (Japan SLC, Shizuoka, Japan). Tumors were allowed to develop for 2 days. Tumor volumes were measured every 2 days according to the formula V = a x b 2 /2 (a, largest superficial diameter; b, smallest superficial diameter). Three and 10 days after transplantation, intratumoral injections were given to three mice within each group. The first group was injected with PBS (phosphate-buffered saline), the second group was injected with a mixture of pAd-Track-CMV inserted in β-galactosidase gene and HVJ envelope vector, and the third group was injected with a mixture of pAd-Track-CMV inserted in N116Y-Cdel2 gene and HVJ envelope vector. From each plasmid, 75 μg was used.
Results
Construction of modified dominant negative RAS mutant 9 We deleted the C-terminal region of N116Y to construct modified N116Y (Fig. 1A) . N116Y-Cdel1 does not have a CAAX box and N116Y-Cdel2 does not have a CAAX box and hypervariable region. We confirmed that the N116Y-Cdel1 and N116Y-Cdel2 coding regions amplified by PCR are shorter than the original N116Y by agarose gel electrophoresis (Fig. 1B) . In addition, the nucleotide sequence of N116Y-Cdel1 and N116Y-Cdel2 was confirmed by ABI Prism 310 Genetic Analyzer (PE Applied Biosystems, CA, USA).
Suppressive effect of N116Y-Cdel2 on HeLa and PCI43 cells with adenovirus vector in vitro
HeLa and PCI43 cells were infected with AdGFP, AdN116Y-Cdel1 or AdN116Y-Cdel2, and harvested and counted (Fig. 2) . As a result, only AdN116Y-Cdel-2 showed a suppressive effect on both HeLa and PCI43 cells. (Fig. 3) . As a result, three pCMV-3xFLAG control clones, three stable clones expressing N116Y and three stable clones expressing N116Y-Cdel2 were obtained from SW480 cells. Three pCMV-3xFLAG control clones and three stable clones expressing N116Y-Cdel2 were also obtained from SAS cells; however, stable clones expressing N116Y-Cdel2 were not obtained from LoVo cells.
Morphological change of stable clones expressing N116Y-Cdel2
The morphological change of stable clones was examined (Fig. 4) . Little or no difference was apparent in pCMV-3xFLAG control clones compared to parental SW480 cells and control clones showed crisscross patterns of growth.
Whereas, like stable clones of SW480 cells expressing N116Y, stable clones expressing N116Y-Cdel2 were morphologically changed and did not show crisscross patterns. Similar morphological change was also observed in stable clones of SAS cells expressing N116Y-Cdel2.
Suppressive effect of N116Y-Cdel2 on SW480 and SAS cells in vitro
The suppressive effect of N116Y-Cdel2 on SW480 and SAS cells was examined by growth curve analysis of stable clones expressing N116Y-Cdel2 11 ( Fig. 5) . As a result, like stable clones of SW480 cells expressing N116Y, stable clones expressing N116Y-Cdel2 showed slow growth, and the average cell number of clones was less than 50 % of that of pCMV-3xFLAG control clones at 5 days after beginning culture. The average cell number of stable clones of SAS cells expressing N116Y-Cdel2 was also less than 50 % that of pCMV-3xFLAG control clones at 5 days after beginning culture.
Suppressive effect of N116Y-Cdel2 on LoVo cells in vitro
As stable clones of LoVo cells expressing N116Y-Cdel2 were not obtained, the suppressive effect of N116Y-Cdel2 on LoVo cells was examined by the observation of colony inhibition assay (Fig. 6 ). LoVo cells were transfected with pCMV-3xFLAG, pCMV-3xFLAG inserted in N116Y gene or pCMV-3xFLAG inserted in N116Y-Cdel2 gene, and then the number of neomycin-resistant cells was counted. As a result, about 70 cell colonies transfected with pCMV-3xFLAG were observed; however, cell colonies transfected with pCMV-3xFLAG inserted in N116Y or N116Y-Cdel2 gene were not confirmed.
Suppressive effect of N116Y-Cdel2 on LoVo cells with non-viral vector in vivo
We examined the suppressive effect of N116Y-Cdel2 on LoVo cells in vivo using the method of gene transfection with HVJ envelope vector (Fig. 7) . 
Discussion
N116Y-Cdel1 and N116Y-Cdel2 were constructed in this study. As activation of the RAS oncogene product needs to be anchored in the plasma membrane to function, and the RAS oncogene product must have its carboxyl terminus farnesylated to be anchored 17, 18) , it is highly likely that C-terminal-deleted N116Y has much lower chance to become oncogenic than N116Y.
N116Y-Cdel2 showed a growth-suppressing effect on HeLa, PCI43, SW480, LoVo and SAS cells. Morphological change was observed in SW480 and SAS cells expressing N116Y-Cdel2, whereas N116Y-Cdel1 did not show a suppressive effect on HeLa and PCI43 cells, although the deleted region of N116Y-Cdel1 was shorter than that of N116Y-Cdel2. it is highly likely that N116Y-Cdel1 lost the suppressive effect of the dominant negative RAS mutant as a result of its biological structure.
N116Y-Cdel2 was constructed from N116Y, which is constructed by 13 mutating (Asn116−>Tyr) in v-H-RAS. This amino acid site of 116 is important to bind with GTP; therefore, N116Y loses function to stimulate cell growth 8) . Hwang et al. reported that N116I, which is biochemically identical to N116Y, binds with SDC25C (Saccharomyces cerevisiae SDC25 C-domain gene product) and suppresses the GDP/GTP exchange reaction of H-RAS 19) .
It was also reported that the growth of renal cell carcinoma cells, which overexpress hSOS-1 (human GEP), was suppressed by N116Y 20) .
N116Y-Cdel2 as well as N116Y has a GEP-binding region. Therefore, it is reasonable to speculate that N116Y-Cdel2 and N116Y competitively inhibit interaction between the RAS oncogene product and GEP. As a result, it is highly likely that signal transmission from the RAS oncogene product was inhibited, and morphological change and suppressive effect were caused, respectively, by the inhibition of RAC activation 21, 22) and MAPK family activation [23] [24] [25] [26] . Moreover, it was confirmed that N116Y suppresses cancer cell growth and induces apoptosis of bladder cancer, pancreatic cancer and leukemia cells by the inhibition of signal transmission [8] [9] [10] [11] [12] [13] [14] . It is also reported phosphorylation of Erk which is important for cell division was inhibited by Confirmation of the expression of N116Y and N116Y-Cdel2 in stable clones 19 by Western blot analysis. The expression of N116Y and N116Y-Cdel2 fused with 3 x FLAG was detected by anti-FLAG tag antibody in pCMV-3xFLAG control clones (Neo), stable clones expressing N116Y (N116Y) and stable clones expressing N116Y-Cdel2 (Cdel2).
Figure 4
Morphological change of stable clones expressing N116Y-Cdel2.
pCMV-3xFLAG control clones, stable clones expressing N116Y and stable clones expressing N116Y-Cdel2 were examined in SW480 cells using a phase microscope (x 200). Each cell was grown to 100% confluence. 
